Filing Details
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) filed a Form 8-K with the Securities and Exchange Commission on July 07, 2026, disclosing a material event.
8k filedNASDAQ:SPRY
ARS Pharmaceuticals, Inc. (SPRY) Reports Material Event to SEC
Filing Details ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) filed a Form 8-K with the Securities and Exchange Commission on July 07, 2026, disclosing a material event. Market Context…
Market Context
ARS Pharmaceuticals, Inc.'s stock currently trades at $8.19 with a market capitalization of $1.1B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for ARS Pharmaceuticals, Inc.'s stock.
All SEC filings for ARS Pharmaceuticals, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SPRY Stock Page
Frequently Asked Questions
Where can I read SPRY's SEC filings?
Browse all filings on our SPRY SEC filings page.
What types of SEC filings does ARS Pharmaceuticals, Inc. file?
Public companies like ARS Pharmaceuticals, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.